Gilenya Sales Data

Rank 52 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Gilenya U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 52 (1) 4.05% 4.92%
Q3 2013 53 (1) 0.49% -1.61%
Q2 2013 52 (15) 10.75% 10.71%
Q1 2013 67 (1) 1.18% -1.75%
Q4 2012 66 (4) 5.17% 3.64%
Q3 2012 70 (17) 21.19% 12.24%
Q2 2012 87 ()

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
October 4, 2013Gilenya Reduces MS Relapse Rates
September 25, 2013Novartis: Study Confirms Long-Term Efficacy of Gilenya
April 20, 2012Novartis Updates US Label on Gilenya Following Discussions With the FDA
April 20, 2012European Medicines Agency Gives New Advice to Better Manage Risk of Adverse Effects on the Heart With Gilenya
December 21, 2011FDA Drug Safety Communication: Safety Review of a Reported Death after the First Dose of Multiple Sclerosis Drug Gilenya (fingolimod)
January 31, 2011New Oral Drugs Hailed for Treating Multiple Sclerosis
September 22, 2010FDA Approves Gilenya - 1st Oral Drug for MS Relapses
September 22, 2010Gilenya Approved for Relapsing MS

Learn how medication, diet, and exercise are key to managing Multiple Sclerosis. Click Here

Close
Hide
(web3)